YM BioSciences Inc. (YM), is a drug development company. The Company is advancing three clinical-stage hematology and cancer-related products. Its CYT387, is an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The Company conducts and outsources clinical trials and also out source the manufacture of clinical materials to third parties. It focuses to co-develop and/or license the rights to manufacture or market its products in development to other pharmaceutical companies in exchange for license fees and royalty payments. YM�s portfolio contains a library of novel small molecules with development potential.